Candida albicans is the leading cause of fungal infections in humans. Despite available therapy options mortality rates reach up to 50%, a rate that highlights the shortcomings of current therapy strategies. Developing new antifungal strategies, therefore, remains a pressing need.

Our initial hypothesis towards improved fungal drug treatment relied on combination antifungal therapy, where two agents combined would be significantly more efficacious compared to either agent alone. In two proof-of-concept studies, we have firmly established this approach ^[1,2].